Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chintu, Desai"'
Autor:
Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Mototsugu Oya, Neal Shore, Eugenia Loredo, Giuseppe Procopio, Juliana de Menezes, Gustavo Girotto, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürmann, Jae Y. Joung, Mikio Sugimoto, Juan A. Virizuela, Urban Emmenegger, Jiri Navratil, Gary L. Buchschacher, Christian Poehlein, Elizabeth A. Harrington, Chintu Desai, Jinyu Kang, Fred Saad
Publikováno v:
NEJM Evidence. 1
Publikováno v:
New England Journal of Medicine. 384:1174-1176
Autor:
Fred Saad, Andrew J. Armstrong, Antoine Thiery-Vuillemin, Mototsugu Oya, Eugenia Loredo, Giuseppe Procopio, Juliana Janoski de Menezes, Gustavo Colagiovanni Girotto, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürmann, Jae Young Joung, Mikio Sugimoto, Christian Heinrich Poehlein, Elizabeth Harrington, Chintu Desai, Jinyu Kang, Noel Clarke
Publikováno v:
Journal of Clinical Oncology. 40:11-11
11 Background: Preclinical studies have shown combined anti-tumor effect through interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor signaling pathways. A Phase II trial (NCT01972217) in pts with mCRPC unselecte
Autor:
Susan Feyerabend, Emmanuelle Bompas, Craig Gedye, Fred Saad, Niven Mehra, Elizabeth A. Harrington, Kazuo Nishimura, Maha Hussain, Nobuaki Matsubara, Neal D. Shore, Chintu Desai, Nicolas Penel, Karim Fizazi, Johann S. de Bono, Joaquin Mateo, J. Burgents, Jinyu Kang, Gwenaelle Gravis, Jae Young Joung, Michael Paul Kolinsky
Publikováno v:
Journal of Clinical Oncology. 39:126-126
126 Background: The Phase 3 PROfound trial (NCT02987543) met its primary endpoint and key secondary endpoints, including improved overall survival (OS) for olaparib in men with mCRPC with alterations in BRCA1, BRCA2, or ATM (Cohort A). We report gene
Autor:
Ronald F van Vollenhoven, Chintu Desai, Vibeke Strand, David Mason, Paul Emery, Philip J. Mease, Edward C. Keystone, Désirée van der Heijde, Karel Pavelka, Bernard Combe, Robert Landewé
Publikováno v:
Arthritis & Rheumatism. 58:3319-3329
Objective To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti–tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA)
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.